Venture Creation Spotlight: Jeremy Caldwell (Versant Ventures)
Company: Lycia Therapeutics
What if we could harness our cell’s lysosomal degradation mechanisms to target and break down disease causing proteins? Versant Ventures is taking this question head on with the creation of Lycia, a biotechnology company using LYTAC (lysosomal targeting chimera) protein degraders to target both soluble and membrane bound extracellular proteins. Nucleate was thrilled to have Jeremy Caldwell speak about the inception and creation of Lycia, and teach us about the Versant Ventures’ model of venture creation!
If you have enjoyed Nucleate’s Venture Creation Seminar Series and would like to learn more about the Venture Creation process, check out our Genesis Program at [ Ссылка ]. This virtual, hands-on educational curriculum teaches scientists to turn ideas into viable biotech ventures. Participants will apply core principles of biotech company creation around Nucleate's venture prompts and pitch an esteemed expert panel.
ABOUT NUCLEATE
Nucleate is a student-run nonprofit that empowers academic trainees to start new life science startups. You can find out more about Nucleate here [ Ссылка ].
Links:
Versant Ventures: [ Ссылка ]
Jeremy Caldwell: [ Ссылка ]
Lycia Therapeutics: [ Ссылка ]
